Dupilumab-associated conjunctivitis - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Dupilumab‑Associated Conjunctivitis: A Comprehensive Patient Guide

Dupilumab‑Associated Conjunctivitis

Overview

Dupilumab (brand name Dupixent) is a monoclonal antibody that blocks interleukin‑4 (IL‑4) and interleukin‑13 (IL‑13) signaling. It is approved for moderate‑to‑severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyps, and some other type‑2 inflammatory diseases. While dupilumab dramatically improves skin and respiratory symptoms, a notable side effect is the development of conjunctivitis (inflammation of the conjunctiva, the thin membrane that lines the eyelid and covers the white of the eye).

  • Who it affects: Most reports involve adult patients with AD, but children (≥6 years) and patients with asthma can also develop it.
  • Prevalence: Clinical trials reported conjunctivitis in 8–22 % of dupilumab‑treated AD patients, compared with 2–5 % in placebo groups. Real‑world registries show a similar range, with higher rates (up to 30 %) in those with a prior history of eye disease.[1][2]

Symptoms

Conjunctivitis can vary from mild irritation to severe keratoconjunctivitis. Common symptoms include:

  • Redness: Pink or blood‑shot appearance of the white of the eye.
  • Itching or burning: Often described as a gritty sensation.
  • Tearing or watering: Excessive tear production.
  • Discharge: Clear, mucoid, or purulent secretion.
  • Sensitivity to light (photophobia): Discomfort in bright environments.
  • Blurred vision: May be transient but warrants prompt evaluation.
  • Swelling of the eyelids: Mild edema around the lashes.
  • Foreign‑body sensation: Feeling that something is in the eye.
  • Dryness or gritty feeling: Paradoxically, some patients report dryness alongside redness.

Symptoms typically emerge within the first 4–12 weeks after starting dupilumab, but can appear later or persist after the drug is stopped.[3]

Causes and Risk Factors

Underlying Mechanism

Dupilumab blocks IL‑4/IL‑13 pathways, which are central to type‑2 inflammation. While this reduces skin and airway inflammation, it also alters the ocular surface immune environment:

  • Reduced mucin production by goblet cells → less tear film stability.
  • Shift toward a Th1‑type response that may provoke ocular surface inflammation.
  • Unmasking of subclinical allergic conjunctivitis already present in many AD patients.

Risk Factors

  • Pre‑existing atopic eye disease: History of allergic conjunctivitis, eczema‑related blepharitis, or dry eye.
  • Severe atopic dermatitis: Higher Eczema Area and Severity Index (EASI) scores correlate with increased risk.
  • Age: Adults >40 years show slightly higher incidence, possibly due to age‑related tear film changes.
  • Concomitant eye‑drop use: Chronic steroid or antihistamine drops may predispose to infection when immune balance shifts.
  • Other biologics: Prior exposure to other monoclonal antibodies (e.g., secukinumab) does not seem protective and may increase overall immune modulation.

Diagnosis

Diagnosing dupilumab‑associated conjunctivitis involves a combination of clinical evaluation and targeted investigations.

Clinical Evaluation

  • History: Timing of symptom onset relative to dupilumab initiation, prior eye conditions, and other medications.
  • Physical exam: Slit‑lamp examination by an ophthalmologist to assess redness, papillary reaction, corneal involvement, and tear film quality.

Diagnostic Tests

  • Fluorescein staining: Detects corneal epithelial defects.
  • Schirmer test: Measures tear production; values <10 mm/5 min suggest dry eye component.
  • Impression cytology (rare): Can evaluate goblet cell density if the diagnosis is uncertain.
  • Microbial cultures: Performed if a bacterial or viral superinfection is suspected.

In most cases, a thorough eye exam is sufficient; laboratory tests are reserved for atypical presentations.

Treatment Options

Management aims to relieve symptoms, protect the ocular surface, and allow continuation of dupilumab when possible.

Topical Medications

  • Artificial tears: Preservative‑free lubricants used 4–6 times daily.
  • Topical corticosteroids: Low‑potency agents (e.g., loteprednol 0.5 %) for short‑term control of inflammation. Taper over 2–4 weeks to avoid glaucoma or cataract risk.
  • Topical calcineurin inhibitors: Cyclosporine 0.05 % or tacrolimus 0.03 % eye drops help improve tear film and reduce inflammation without steroid side effects.
  • Antihistamine/mast‑cell stabilizer drops: For patients with a clear allergic component (e.g., olopatadine).
  • Antibiotic ointments: If a bacterial superinfection is present (e.g., erythromycin ophthalmic ointment).

Systemic Adjustments

  • Dupilumab dose interruption: Temporary hold (1–2 weeks) may be considered if severe inflammation does not respond to topical therapy.[4]
  • Switching therapy: In refractory cases, clinicians may discuss alternative biologics (e.g., tralokinumab) after weighing benefits.

Procedural Interventions

  • Punctal plugs: Small silicone devices placed in tear duct openings to retain tears; helpful for dry‑eye‑dominant cases.
  • Corneal debridement: Rarely required for persistent epithelial defects.

Lifestyle & Adjunct Measures

  • Warm compresses 5–10 minutes twice daily to improve meibomian gland function.
  • Humidifier use in dry indoor environments.
  • Avoidance of contact lens wear during active inflammation.
  • Protection from wind, smoke, and irritants.

Living with Dupilumab‑Associated Conjunctivitis

While the condition can be uncomfortable, most patients manage it successfully with a structured plan.

Daily Management Tips

  • Establish a drop schedule: Use a reminder app to ensure regular application of lubricants and anti‑inflammatory drops.
  • Practice good eyelid hygiene: Gentle cleaning with a cotton swab dipped in diluted baby shampoo or commercially available eyelid wipes.
  • Monitor vision: Keep a simple log of any changes in visual acuity or new photophobia.
  • Stay hydrated: Adequate water intake supports tear production.
  • Regular ophthalmology follow‑up: Initially every 2–4 weeks, then spacing out as symptoms improve.

Impact on Quality of Life

Studies using the Dermatology Life Quality Index (DLQI) show that patients who develop conjunctivitis report a modest but significant increase in daily discomfort scores. Early treatment and education can mitigate this impact.[5]

Prevention

Preventive strategies focus on identifying at‑risk individuals and implementing protective measures before symptoms arise.

  • Baseline eye exam: Obtain an ophthalmologic assessment before starting dupilumab, especially if a history of eye disease exists.
  • Prophylactic lubricants: Start preservative‑free artificial tears at dupilumab initiation for high‑risk patients.
  • Allergy control: Keep seasonal allergies under control with oral antihistamines to reduce ocular surface irritation.
  • Environmental modifications: Use humidifiers, avoid smoky or dusty settings, and wear protective sunglasses outdoors.
  • Educate patients: Provide written instructions on early signs of conjunctivitis and when to contact their eye doctor.

Complications

If left untreated, conjunctivitis can progress to more serious ocular problems:

  • Keratitis: Inflammation of the cornea that can cause scarring and permanent vision loss.
  • Secondary bacterial infection: Presents with purulent discharge and may require systemic antibiotics.
  • Chronic dry eye syndrome: Persistent tear film instability leading to ongoing discomfort.
  • Glaucoma or cataract: Long‑term use of high‑potency steroid drops can raise intra‑ocular pressure.

Early intervention reduces the risk of these outcomes dramatically.[6]

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden severe eye pain or a feeling of a foreign body that does not improve with irrigation.
  • Rapid worsening of vision (blurry, double, or loss of vision).
  • Marked swelling of the eyelids with fever (possible orbital cellulitis).
  • Bright red eye with heavy discharge accompanied by severe headache.
  • Photophobia so intense that you cannot keep your eyes open.
These signs may indicate corneal ulceration, infection, or other sight‑threatening conditions that need immediate treatment.

References

  1. Simpson EL, et al. “Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.” JAMA Dermatology. 2020;156(9):939‑947.
  2. Gordon KB, et al. “Real‑world incidence of dupilumab‑associated conjunctivitis.” British Journal of Dermatology. 2022;186(4):653‑660.
  3. Wollenberg A, et al. “Ocular side effects of dupilumab: a systematic review.” Ocular Immunology and Inflammation. 2021;29(3):387‑397.
  4. National Psoriasis Foundation. “Guidelines for management of dupilumab‑related eye disease.” 2023. https://www.psoriasis.org
  5. Chamlin SL, et al. “Quality‑of‑life impact of dupilumab‑associated conjunctivitis.” Dermatology Therapy. 2023;13(2):215‑224.
  6. American Academy of Ophthalmology. “Conjunctivitis: When to worry.” 2022. https://www.aao.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References